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ABSTRACT
Intercellular adhesion molecule-1 (ICAM-1) is distributed and expressed on cell surface and is present in circulation as soluble form (sICAM-1).
Tumor necrosis factor-alpha (TNFa) and radical oxygen species (ROS) up-regulate the expression of ICAM-1. This studydemonstrates for thefirst
time in 18 Co cells, a myofibroblast cell line derived from human colonic mucosa, an up-regulation of ICAM-1 expression and sICAM-1 release
induced by oxidative stress and TNFa stimulation. The intracellular redox state was modulated by L-buthionine-S,R-sulfoximine (BSO) or
N-acetylcysteine (NAC), inhibitor and precursor respectively of GSH synthesis. ROS production increases in cells treated with BSO or TNFa, and
this has been related to an up-regulation of ICAM-1 expression and sICAM-1 release. The involvement of metalloproteinases in ICAM-1 release
has been demonstrated. Moreover, also expression and activation of A disintegrin andmetalloproteinase 17, amembrane-bound enzyme known
as TNFa-converting enzyme (TACE), have been related to ROS levels. This suggests the possible involvement of TACE in the cleavage of ICAM-1
oncell surface in condition of oxidative stress. NACdown-regulates the expression and release of ICAM-1aswell as the expression and activation
of TACE. However, in TNFa stimulated cells NAC treatment reduces only in part ICAM-1 expression and sICAM-1 release. Given this TNFamay
also act on these events by a redox-independent mechanism. J. Cell. Biochem. 117: 370–381, 2016. © 2015 Wiley Periodicals, Inc.
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Intercellular adhesion molecule-1 (ICAM-1) is a glycoproteinextensively distributed and expressed on cell surface of various
cell types such as fibroblasts, endothelial and epithelial cells, and
leukocytes [Hua, 2013]. The role of ICAM-1 is crucial in immune
response inducing the trans-migration of leukocytes to inflamma-
tory sites. ICAM-1 alsomediates the intracellular signal transduction
pathway, through outside-in signalling event, and the cell-matrix
adhesion. Moreover, it promotes the adhesion of cancer cells and is
involved in the immune response of tumors [Lawson andWolf, 2009;
Arteta et al., 2010; Ksiazek et al., 2010]. In addition, ICAM-1 is
present in circulation as soluble form (sICAM-1), lacking the
transmembrane and cytoplasmic domains. sICAM-1 results from
proteolytic cleavage of cell surface ICAM-1 through a process that
does not depend on the amount of ICAM-1 present on membranes
[Lawson and Wolf, 2009; Hua, 2013]. In particular, proteases
involved in ICAM-1 cleavage are matrix metalloproteinases (MMPs)
[Lawson and Wolf, 2009], A disintegrin and metalloproteinase 17, a
membrane-bound enzyme known as tumor necrosis factor-alpha
(TNFa) -converting enzyme (TACE), [Tsakadze et al., 2006] and
elastase, a serine proteinase secreted by neutrophils and macro-
phages during inflammation [Champagne et al., 1998]. Although
sICAM-1 can have a good therapeutic effect by blocking cell-cell
adhesion, it plays a role in chronic inflammatory processes by
stimulating the cytokine production [McCabe et al., 1993; Otto et al.,
2000], the activation of mitogen activated protein kinases (MAPK)
[Otto et al., 2002] and transcriptional factors [Schmal et al., 1998].
An up-regulation and/or over-expression of ICAM-1 and sICAM-
1 have been found in tumors, such as melanoma, pancreatic cancer
and colorectal cancer (CRC), suggesting a role of ICAM-1 in the
malignant progression [Maeda et al., 2002; Roland et al., 2007,2010].
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In particular, an increase of ICAM-1 on the surface of neoplastic cells
mediates the attachment of these cells to the extracellular matrix,
with the consequent decrease of metastases and increase of tumor
differentiation [Taglia et al., 2007]. On the contrary, sICAM-1 is
involved in tumor invasion and in development of metastasis in
various cancer types [Nakata et al., 2000; Perabo et al., 2001; Maeda
et al., 2002; O0Hanlon et al., 2002].
Pro-inflammatory mediators, cytokines, and radical oxygen
species (ROS) up-regulate the expression of ICAM-1 [Roebuck and
Finnegan, 1999; Ying et al., 2009; Angel-Morales et al., 2012; Pina-
Canseco Mdel et al., 2012]. In fact, an increased expression of ICAM-
1 occurs in different pathological inflammatory conditions, such as
psoriasis, atherosclerosis, autoimmune diseases and inflammatory
bowel diseases (IBD) [Chatterjee, 1998; Metselaar and Storm, 2005;
Van Assche and Rutgeerts, 2005]. High levels of ICAM-1 expression
have been found in IBD patients and during experimental colitis
[Vainer et al., 2000; Chidlow et al., 2006]. In particular, in patients
with Crohn0s Disease (CD), an enhanced expression of ICAM-1 in the
intestinal mucosa has been demonstrated [Ghosh and Panaccione,
2010]. In addition, high serum levels of sICAM-1, which probably
derive from the cutting of ICAM-1 from cell surface within gut
mucosa, have been measured in CD patients [Nielsen et al., 1994].
High levels of sICAM-1 are also present in serum of patients with
CRC [Alexiou et al., 2001] that represents an elevated risk for IBD
patients [Feagins et al., 2009; Grivennikov, 2013]. A risk factor for
carcinogenesis in IBD patients is the enhanced oxidative state
[O0Connor et al., 2010] present in the intestinalmucosa and intestinal
subepithelial myofibroblasts (ISEMFs) of these patients [Iantomasi
et al., 1994; Buffinton and Doe, 1995; Catarzi et al., 2011a].
ISEMFs, mesenchymal cells localized at interface between
enterocytes and lamina propria, regulate various functions of
normal and tumoral epithelial cells, stimulate colon tumorigenesis
[Pinchuk et al., 2010] and are involved in the colorectal metastases
[Yeung et al., 2013]. Moreover, ISEMFs express adhesion molecules,
such as ICAM-1 [Pang et al., 1994]. In the literature, to our
knowledge, no data are reported on the release of sICAM-1 by these
cells and the redox regulation of ICAM-1 and sICAM-1 in ISEMFs.
In this study, we investigated the role of ROS on ICAM-1
expression and sICAM-1 release in myofibroblasts stimulated or not
by TNFa. Indeed, TNFa is an important pro-inflammatory mediator
related to the regulation of inflammatory signalling pathways in IBD
[Biasi et al., 2013]. Moreover, a redox regulated mechanism of TACE
expression and activation was also investigated. For this purpose, we
performed experiments using a myofibroblast cell line derived from
human colonic mucosa, CCD-18Co (18Co) cells which exhibit many
properties of ISEMFs [Valentich et al., 1997]. In these cells, the
intracellular redox state was modulated by L-buthionine-S,R-
sulfoximine (BSO) or N-acetylcysteine (NAC), inhibitor and
precursor respectively of GSH synthesis [Catarzi et al., 2011a].
MATERIALS AND METHODS
CELL CULTURE AND TREATMENT
CCD-18Co (18Co) cells, obtained from American Type Culture
Collection (Manassas, VA), were used in our experiments with PDL
27–36, given that the line begins to senescence at about PDL¼ 42.
The substances used for cell cultures and cell treatments were
purchased from Sigma (St. Louis, MO). Cells were cultured at 37°C in
a 5% CO2 atmosphere in minimum essential medium with 2mM
glutamine and 1.5 g/L sodium bicarbonate, 0.1mM non-essential
amino acids, 1mM sodium pyruvate and 10% fetal bovine serum.
Culture media were supplemented with 72mg/L penicillin and
100mg/ml streptomycin. Experiments were performed in 18Co cells
serum starved at confluence for 24 h and treated or not during the
last 16 h with 25mM BSO or 20mM NAC or NACþBSO.
Subsequently, the cells were stimulated or not for other 24 h with
various concentrations of TNFa (1–30 ng/ml). Additional experi-
ments were performed in 24 h serum starved 18Co cells treated or
not, during the last 16 h, with BSO in the presence or absence of
10mM TNFa-protease inhibitor-1 (TAPI-1) or 10mM diphenyle-
neiodonium (DPI). In experiments with DPI, we added 0.003%DMSO
(vehicle for DPI) in the respective DPI untreated cells. Subsequently
these cells were stimulated for 24 hwith TNFa. The concentrations of
all compounds used did not reduce the viability according to Trypan
blue exclusion test.
INTRACELLULAR ROS PRODUCTION ASSAY
The intracellular production of ROS was assayed, as previously
described [Catarzi et al., 2011b], in 18Co cells seeded in 12-well
plates, serum starved and treated as above described. Thirty minutes
before the end of the various treatments, 5 g/L 20-70-dichlorodihy-
drofluorescein diacetate (H2DCFDA) was added in culture medium.
After PBS washing, adherent 18Co cells were lysed in 50mM
Tris/HCl pH 7.5, 1% Triton X100, 150mM NaCl, 100mM NaF, 2mM
EGTA (RIPA buffer) and analysed immediately by fluorescence
spectrophotometric analysis at 510 nm. Data have been normalized
on total protein content and values were expressed as percent of
ROS production measured in untreated and unstimulated cells
(control).
ICAM-1 AND sICAM-1 ASSAY
sICAM-1 release and intracellular ICAM-1 levels were measured in
cell lysate and in the respective culture medium, using Human
ICAM-1 ELISA kit (Uscn Life Sciences Inc., Wuhan, Hubei, PRC) in
accordance whit the manufacturer0s instructions. 18Co cells were
seeded in 12-well plates and treated as above described. For the cell
lysates preparation, cells were detachedwith trypsin and collected by
centrifugation at 130g for 10min. Cells, washed three times in cold
phosphate buffer saline (PBS), were resuspended in PBS and
ultrasonicated for 4 times. Subsequently, the cell lysates were
centrifugated at 1,500g for 10min to remove cellular debris and
ICAM-1 assay was performed in the supernatants. Data have been
normalized on total protein content and sICAM-1 and ICAM-1 levels
were expressed as percent of the respective levels measured in
control.
WESTERN BLOTTING
ICAM-1 and TACE expression analysis was performed by Western
blot in 18Co cells seeded in p-60 plates treated and stimulated or
not as above described. Cells were lysed in ice cold RIPA
buffer containing phosphatase and protease inhibitor cocktails,
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purchased from Sigma and, after 15min on ice, were centrifuged
at 11,600g for 10min. Immunochemical detection of ICAM-1 was
performed also in the membrane fraction purified as previously
reported [Catarzi et al., 2005]. Protein concentrations were
determined by the bicinchoninic acid solution (BCA) protein
reagent assay (Pierce) [Smith et al., 1985] using bovine serum
albumin as standard (Sigma). Equal amount of total proteins
(30–35mg) were loaded in each line and were subjected to sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS/PAGE)
on 10% (w/v) gel and electrotransferred to PVDF membrane (GE
Healtcare) that was probed with specific antibodies anti-ICAM-1
or anti- b-actin (Santa Cruz Biotechnology, INC.). For the
detection of TACE and TACE phosphorylated at Thr735, the
samples were lyophilized and 100mg of proteins were subjected to
SDS/PAGE on 10% (w/v) gel. PVDF membranes were probed with
anti-TACE (Santa Cruz Biotechnology, INC.) or anti- b-actin.
Subsequently, the membranes were stripped by incubation for
30min at 50°C in buffer containing 62.5mM Tris/HCl, pH 6.7, 100
nM 2-mercaptoethanol, 2% SDS and, after extensive washing, the
membranes were reprobed with anti-ADAM17-phospho-Thr735
(MyBioSource). b-actin bands were used to normalize and to
perform a densitometric analysis. Secondary antibodies conju-
gated to horseradish peroxidase were used to detect antigen-
antibody complexes with a chemiluminescence reagent kit (GE
Healtcare). Chemidoc-Quantity-One software (Biorad Laborato-
ries) was used to perform quantitative analyses and band values
were expressed as percentage variations relative to controls.
STATISTICAL ANALYSIS
All experiments were carried out four or more times. Data are
expressed as the mean SEM and statistical significance of the
differences was determined using Student0s t test. P 0.05 was
considered statistically significant.
RESULTS
EFFECT OF BSO, NAC, AND TNFaON INTRACELLULAR ROS LEVELS IN
18Co CELLS
In Figure 1 the intracellular ROS productionmeasured in 18Co cells in
different experimental conditions is reported. The cells were treated or
notwithBSOorNACorbothand, subsequently, stimulatedornotwith
1ng/ml TNFa (TNFa 1), physiological concentration [Corredor et al.,
2003], and 10ng/ml TNFa (TNFa 10), concentration at which the
maximum effect has been observed. BSO and TNFa increased
significantly ROS production in 18Co cells as compared to untreated
and unstimulated cells (control) (Fig. 1). Interestingly, TNFa 1
increased ROS levels similarly to that observed in BSO treated cells.
Moreover, it enhanced significantly ROS production in BSO treated
18Co cells, as compared to cells stimulated and treated separatelywith
TNFa or BSO, reaching the value obtained with TNFa 10 (Fig. 1). In
fact, TNFa 10 enhancedROS intracellular levels, as compared to TNFa
1 stimulated 18Co cells, and BSO treatment did not make a further
increase. Figure 1 shows that NAC treatment reduced significantly
ROS levels, as compared to control cells, and this effect was also
observed both in BSO treated cells and TNFa 1 stimulated cells. On the
contrary, NAC restored ROS levels to control values in all the other
conditions (TNFa 10, BSOþ TNFa 1, and BSOþ TNFa 10).
EFFECT OF BSO, NAC, AND TNFa ON ICAM-1 EXPRESSION AND
sICAM-1 RELEASE IN 18Co CELLS
Considering the effects of BSO, NAC, and TNFa on the changes of
intracellular oxidative state, under the same experimental con-
ditions, ICAM-1 expression and sICAM-1 release were detected by
Western blot analysis of cell lysates and by ELISA kit in culture
medium, respectively. Figure 2A shows that ICAM-1 increased both
in BSO treated and TNFa stimulated cells, as compared to control. It
is noteworthy that the enhancement of ICAM-1 expression was
Fig. 1. Intracellular ROS production in 18Co cells treated or not with BSO or NAC and stimulated with TNFa. Starved 18Co cells, treated or not with 25mMBSO or 20mMNAC
as reported in Materials andMethods, were stimulated or not for 24 h with 1ng/ml TNFa (TNFa1) or 10 ng/ml TNFa (TNFa10). The intracellular ROS production was detected by
measuring the fluorescence intensity of the intracellular oxidation-sensitive probe H2DCFDA. The values, normalized on total protein content and expressed as percent of
untreated and unstimulated cells (control, 100%, indicated with the arrow), are the mean SEM of six experiments repeated in triplicate. P 0.05 compared to the control
cells; &P 0.005 compared to NAC untreated and TNFa1 stimulated cells; P 0.001 compared to NAC untreated and BSO treated cells.
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maximum in TNFa 10 stimulated cells and significantly higher than
that measured in TNFa 1 stimulated cells. Both TNFa concentrations
increased significantly ICAM-1 expression as compared to BSO
treated cells. ICAM-1 expression was up-regulated only in BSOþ
TNFa 1 treated 18Co cells, as compared to TNFa 1 stimulated cells,
and the value obtained was significantly lower than that detected in
10 TNFa stimulated cells. No further increase of ICAM-1 expression
was observed in BSOþ TNFa 10, as compared to TNFa 10 stimulated
cells (Fig. 2A). Subsequently, we measured ICAM-1 expression in
18Co cells treated with NAC. Figure 2B shows that NAC treatment in
all conditions down-regulated ICAM-1 expression, but this was
reduced significantly only in NAC and NACþBSO treated cells as
compared to control. In NAC treated cells stimulated with both TNFa
concentrations, the expression of ICAM-1 was higher than that of
control cells but significantly lower than that measured in the
respective TNFa stimulated cells. Moreover, NAC significantly
decreased ICAM-1 expression in both TNFa 1 and BSOþ TNFa 1
cells, as compared to the value measured under the same conditions
in TNFa 10 and BSOþ TNFa 10 stimulated 18Co cells (Fig. 2B). In all
these experimental conditions Western blot was performed on
purified membranes and the results were similar to those obtained in
cell lysates (data not shown). Figure 3 shows that sICAM-1 release
followed roughly the same trend of ICAM-1 expression. Differently
to that occurred for ICAM-1 expression, a similar release of sICAM-1
was measured in BSO treated cells and in TNFa 1 stimulated cells as
compared to control value. Only TNFa 10 was able to enhance
sICAM-1 release with respect to BSO treated 18Co cells. Moreover,
NAC treatment restored the values of sICAM-1 release to control
level in BSO treated cells and in all TNFa 1 stimulated cells but not in
18Co cells stimulated with TNFa 10. In fact, in NAC treated cells
stimulated with TNFa 10 the release of sICAM-1was higher than that
measured in control cells (Fig. 3).
Fig. 2. ICAM-1 expression in 18Co cells treated or not with BSO or NAC and stimulated with TNFa. Starved 18Co cells, treated or not with 25mMBSO (A) or or 20mMNAC (B)
as reported in Materials and Methods, were stimulated or not for 24 h with 1ng/ml TNFa (TNFa1) or 10 ng/ml TNFa (TNFa10). For the detection of ICAM-1 expression Western
blot analysis of cell lysate with anti-ICAM-1 and anti b-actin was performed. Blot is representative of four experiments and the normalized values with actin bands obtained by
densitometric analysis of four experiments are reported in the bottom. The values are the mean percentage SEM relative to those obtained in the untreated and unstimulated
cells (control, 100%, indicated with the arrow). P 0.05 compared to the control cells.&P 0.05 compared to NAC untreated and TNFa1 stimulated cells; P 0.05 compared
to NAC untreated and BSO treated cells; *P 0.05 compared to NAC untreated and BSOþTNFa1 treated cells; DP 0.05 compared to the respective NAC untreated cells;
~P 0.05 compared to the respective NAC treated and TNFa1 stimulated cells.
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INVOLVEMENT OF MMPs AND NADPH OXIDASE ON sICAM-1
RELEASE AND INTRACELLULAR ICAM-1 LEVELS IN 18Co CELLS
TREATED WITH BSO AND STIMULATED WITH TNFa
The involvement of redox regulated MMPs on sICAM-1 release in
18Co cells treated or not with BSO and stimulated with TNFa was
performed by using their inhibitor TAPI-1 [Liu et al., 2014].
Moreover, at the same time, both sICAM-1 release in culture medium
and intracellular ICAM-1 levels in cell lysates were measured by
ELISA kit. Data reported in Figure 4A show that BSO, TNFa, and
BSOþ TNFa, at both concentrations, increased intracellular ICAM-1
in agreement with the expression trend previously detected by
Western blot analysis (Fig. 2A). Under these conditions TAPI-1
significantly up-regulated intracellular ICAM-1 levels (Fig. 4A) and
down-regulated sICAM-1 release (Fig. 4B), as compared to the
respective untreated cells. In particular, TAPI-1 treatment restored
s-ICAM-1 release to control values in TNFa 1 stimulated 18Co cells
treated or not with BSO, but not in all cells stimulated with TNFa 10
(Fig. 4B). Treatment of the cells with DPI, inhibitor of NADPH
oxidase major producer of ROS in many cells [Panday et al., 2015],
inhibited markedly both intracellular ICAM-1 and sICAM-1 release
in all conditions used, as compared to the respective untreated 18Co
cells (Fig. 4A, B), in accordance with the results obtained with NAC
(Figs. 2B and 3). In fact, Figure 5 shows that DPI reduced also ROS
production in agreement with the behavior of ROS detected in the
same conditions with NAC treatment (Fig. 1).
EFFECT OF BSO, NAC, DPI, AND TNFa ON TACE EXPRESSION AND
ACTIVATION IN 18Co CELLS
TACE expression and activation, detected by Western blot assay,
were measured by densitometric analysis of pro-TACE at 120 kDa
and mature (active) TACE at 80 kDa bands, respectively. These
enhanced both in BSO treated and in TNFa stimulated cells, as
compared to the respective controls (Fig. 6A). Both expression and
activation of TACE significantly increased in TNFa 1þBSO cells,
when compared with 18Co BSO treated or TNFa 1 stimulated cells,
reaching the values measured in all cells stimulated with TNFa 10.
Thr735 phosphorylation of TACE cytoplasmic tail is very important
for TACE mobilization to plasma membrane and activation [Scheller
et al., 2011]. The use of a specific antibody, which detects
endogenous levels of TACE phosphorylation only when phosphory-
lated at Thr735, shows that the trend of this phosphorylation,
relative to 80 kDa band, was similar to that of TACE activation in all
conditions used (Fig. 6A). However, the proportion of TACE
phosphorylated, calculated by ratio between bands of TACE
P-Thr735 and those of pro-TACE (120 kDa), was similar in all
conditions (Fig. 6B). Moreover, Figure 6B shows also that mature
TACEwas all phosphorylated, as indicated by ratio between bands of
TACE P-Thr735 and those of TACE at 80 kDa. Treatment with NAC
and DPI restored TACE expression, activation and phosphorylation
to values of control in all conditions (Fig. 7A, B).
DISCUSSION
In the present study, we examined the role of intracellular oxidative
stress on ICAM-1 expression and sICAM-1 release in 18Co cells
stimulated or not with TNFa. In particular, we demonstrated, for the
first time, an increase of ICAM-1 expression and sICAM-1 release in
condition of oxidative stress in 18Co cells. The involvement of redox
regulated MMPs in the up-regulation of sICAM-1 release has been
also demonstrated. Moreover, this study shows ROS dependent
increase of TACE activation and expression suggesting its possible
Fig. 3. sICAM-1 levels in 18Co cells treated or not with BSO or NAC and stimulated with TNFa. Starved cells, treated or not with 25mM BSO or 20mM NAC as reported in
Materials and Methods, were stimulated or not for 24 h with 1 ng/ml TNFa (TNFa1) or 10 ng/ml TNFa (TNFa10). The culture medium was collected and used for sICAM-1 assay
by immunoenzymatic method. The values, expressed as percent of untreated and unstimulated cells (control, 100%, indicated with the arrow), are the mean SEM of six
experiments repeated in triplicate. P 0.05 compared to the control cells. &P 0.05 compared to NAC untreated and TNFa1 stimulated cells. P 0.05 compared to NAC
untreated and BSO treated cells; ~P 0.05 compared to the respective NAC treated and TNFa1 stimulated cells.
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role in the up-regulation of sICAM-1 release. In particular, BSO
treatment or TNFa stimulation of 18Co cells induce a rise of ROS
production related to an increase of ICAM-1 expression and
sICAM-1 release. In fact, NAC and DPI treatments reduce or restore
ROS production to control and down-regulate ICAM-1 expression
and release. TNFa causes oxidative stress [Woo et al., 2000; Lee et al.,
2013] and induces ROS production in a concentration-dependent
manner. However, in BSO treated cells, only the physiological
concentration of TNFa (1 ng/ml) is able to increase ROS production
reaching the value obtained in cells stimulated with 10 ng/ml TNFa.
This suggests that TNFa at physiological concentrations, in the
presence of intracellular oxidative stress, increases this inducing
tissue damage as it occurs in pathological concentrations. This is
particularly important in pathologies, as IBD, in which a condition of
oxidative stress is present [Iantomasi et al., 1994; Buffinton and Doe,
1995; O0Connor et al., 2010; Catarzi et al., 2011a]. It is to note that
ROS production is similar in BSO treated or TNFa 1 stimulated cells
whereas ICAM-1 expression is different. In fact, ICAM-1 expression
is higher in TNFa 1 stimulated cells than in cells treated with BSO.
NAC treatment down-regulates ICAM-1 expression only in control
and in BSO treated 18Co cells in according to ROS levels. NAC lowers
the expression of ICAM-1 levels, but is not able to restore them to the
control values in cells stimulated with both concentrations of TNFa,
differently to that occurs for ROS production. These results indicate
that the up-regulation of ICAM-1 expression in TNFa stimulated
18Co cells, is partially dependent on ROS production and is related to
TNFa concentrations through a ROS-independent mechanism.
Oxidative stress induces ICAM-1 expression [Roebuck et al.,
Fig. 4. Effect of TAPI-1 and DPI on intracellular ICAM-1 levels and sICAM-1 levels in 18Co cells treated or not with BSO and stimulatedwith TNFa. 10mMTAPI-1 or 10mMDPI
were added to starved cells treated or not with 25mMBSO and stimulated or not for 24 h with 1 ng/ml TNFa (TNFa 1) or 10 ng/ml TNFa (TNFa10), as reported in Materials and
Methods. Intracellular ICAM-1 levels (A) and sICAM-1 (B) assays were performed by ELISA kit in cell lysates and in culture medium, respectively. The values, expressed as percent
of untreated and unstimulated cells (control, 100%, indicated with the arrow), are the mean SEM of six experiments repeated in triplicate. P 0.05 compared to the control
cells; §P 0.05 compared to the respective untreated cells; ~P 0.05 compared to the respective TNFa 1 stimulated cells.
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1995] whose redox regulation occurs at different levels being cell
type- and stimulus-dependent [Roebuck and Finnegan, 1999]. In
lung epithelial cells, TNFa-induced ICAM-1 increase is due to the
activation of redox regulated signaling pathways, and in fact, it is
inhibited by pre-treatment with NADPH-oxidase inhibitor or
antioxidants [Kim et al., 2008; Lee et al., 2013; Yen et al., 2013].
However, in endothelial cells TNFa stimulation of ICAM-1 is
different from that induced by exogenous H2O2 [Roebuck and
Finnegan, 1999], and the down-regulation of TNFa-induced
myogenesis occurs in murine skeletal muscle cells through redox-
dependent and -independent pathways [Langen et al., 2002]. The
treatment of 18Co cells with DPI demonstrates the possible
involvement of NADPH oxidase in the increase of ICAM-1 levels;
in fact this enzyme represents the principal source of ROS induced by
TNFa [Li et al., 2005]. However, DPI, similarly to NAC, reduces ROS
levels, but does not remove totally the effect of TNFa on ICAM-1
expression. This confirms also the involvement of a redox-
independent regulation in the increase of TNFa-induced ICAM-1
expression in 18Co cells.
A closer relationship is demonstrated between sICAM-1 release
and the oxidative stress. This is especially evident in 18Co cells
treated with BSO or stimulated with TNFa 1, also in the presence of
NAC and DPI treatments. On the contrary, sICAM-1 release in TNFa
10 stimulated cells is only in part related to ROS production, given
that NAC and DPI do not restore sICAM-1 levels to those of control,
differently to that occurs for ROS levels. Therefore, we suggest that
TNFa at high concentrations up-regulates sICAM-1 release also by
activating other redox-independent mechanisms responsible for
proteolytic cleavage of cell surface ICAM-1. sICAM-1 release was
significantly inhibited by TAPI-1, indicating that redox regulated
MMPs are involved in the cleavage of transmembrane ICAM-1
induced by oxidative stress in 18Co cells. Alterations of the cellular
redox state may regulate both activation and expression of TACE, a
protease that cleaves membrane-bound proteins [Scheller et al.,
2011]. However, in literature no data are reported on the expression,
activation and regulation of this enzyme in ISEMFs in the presence
or not of changes in intracellular oxidative state. For the first time, in
18Co cells an up-regulation of the expression and activation of
TACE, related to intracellular oxidative stress, has been demon-
strated. In fact, TACE expression and activation correlate with ROS
levels in cells treated with BSO and/or stimulated with TNFa.
Moreover, NAC and DPI treatments restore them to control values in
all conditions. Given this and considering that some authors indicate
TAPI-1 as specific inhibitor of TACE [Liu et al., 2014], a possible role
of TACE in the cleavage of ICAM-1 in the presence of oxidative stress
cannot be excluded. The simultaneous enhancement of endogenous
ICAM-1 detected in TAPI-1 treated cells can be due to the inhibition
of ICAM-1 shedding. Moreover, it is also possible that, in TNFa
treated cells, TAPI-1 blocks TACE-mediated generation of antago-
nistic soluble TNFa receptors [Scheller et al., 2011]. This can increase
ICAM-1 expression trough an enhanced cell stimulation by TNFa.
Exogenous H2O2 activates TACE, involving the cysteinyl sulphydryl
groups in the extracellular domain [Wang et al., 2009], and increases
its cell surface expression via p38-mediated TACE phosphorylation
[Brill et al., 2009]. In fact, the activation of this MAPK leads to
specific phosphorylation of Thr735 involved in the TACE trans-
location to membrane and activation. In our conditions, the trend of
Thr735 phosphorylation relative to 80 kDa band agrees with TACE
activation and it is related to ROS levels. The increased phosphory-
lation of TACE correlates with the up-regulation of its expression. In
fact, the absolute values of TACE phosphorylation change, whereas
the proportion of phosphorylated TACE is similar in all conditions.
We suggest the involvement of p38MAPK on TACE phophorylation,
considering that a redox-regulated activation of thisMAPK occurs in
18Co cells stimulated or not with TNFa and in ISEMFs isolated from
intestine of CD patients [Catarzi et al., 2011a]. Therefore, the redox
Fig. 5. Effect of DPI on intracellular ROS production in 18Co cells treated with BSO and stimulated with TNFa. Starved 18Co cells, treated or not with 25mM BSO in the
presence of 10mM DPI as reported in Materials and Methods, were stimulated or not for 24 h with 1 ng/ml TNFa (TNFa1) or 10 ng/ml TNFa (TNFa10). 0.003% DMSO (vehicle
for DPI) was added to DPI untreated cells. The intracellular ROS production was detected by measuring the fluorescence intensity of the intracellular oxidation-sensitive probe
H2DCFDA. The values, normalized on total protein content and expressed as percent of untreated and unstimulated cells (control, 100%, indicated with the arrow), are the
mean SEM of six experiments repeated in triplicate. P 0.05 compared to the control cells; &P 0.005 compared to DPI untreated and TNFa1 stimulated cells; P 0.001
compared to DPI untreated and BSO treated cells.
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regulation of TACE expression and activation, detected in intestinal
myofibroblasts by us, may be involved in the pro-inflammatory
activity of TNFa in inflamed gut. In fact, myofibroblasts produce
TNFa in intestinal inflammatory state and, in CD patients, they show
high expression of transmembrane TNFa [Di Sabatino et al., 2007].
Moreover, TACE is required in cell surface proteolytic processing of
TNFa that after cleavage assumes its inflammatory properties
[Scheller et al., 2011].
ICAM-1 is involved in the recruitment of immune cells at
inflammatory sites, and the infiltration and migration of leukocytes
into inflamed intestinal mucosa and submucosal layers are crucial
for the pathogenesis of IBD [Binion et al., 2009]. ISEMFs produce
molecules that contribute to this migration [Pinchuk et al., 2010],
therefore the up-regulation of ICAM-1 induced by oxidative stress
and TNFa stimulation in ISEMFs can be involved in the excessive
migration of leukocytes to the site of local gastrointestinal mucosal
Fig. 6. TACE expression and activation in 18Co cells treated or not with BSO and stimulated with TNFa. Starved cells, treated or not with 25mM BSO as reported in Materials
and Methods, were stimulated or not for 24 h with 1 ng/ml TNFa (TNFa1) or 10 ng/ml TNFa (TNFa10). Western blot analysis of cell lysate with anti-TACE or anti-ADAM17-
phosphoThr735 or antib-actin was performed for the detection of TACE expression and activation. The TACE P-Thr735 was detected on 80 kDa band. A: Blots are representative
of four experiments and normalized values with actin band obtained by densitometric analysis of four experiments are reported in the bottom. The values are the mean
percentage SEM relative to those obtained in the untreated and unstimulated cells (control, 100%). B: The proportion of TACE phosphorylated was calculated both by ratio
between bands of TACE P-Thr735 and those of pro-TACE (120 kDa) and by ratio between bands of TACE P-Thr735 and those of mature TACE (80 kDa). P 0.005 compared to
the control cells. &P 0.05 compared to the respective TNFa1 stimulated cells P 0.05 compared to the respective BSO treated cells.
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Fig. 7. Effect of NAC or DPI on TACE expression and activation in 18Co cells treated or not with BSO and stimulated with TNFa. 20mMNAC or 10mMDPI were added to starved
cells treated or not with 25mM BSO and stimulated or not for 24 h with 1 ng/ml TNFa (TNFa1) or 10 ng/ml TNFa (TNFa10), as reported in Materials and Methods. 0.003%
DMSO (vehicle for DPI) was added to DPI untreated cells. Western blot analysis of cell lysate with anti-TACE or anti-ADAM17-phosphoThr735 or antib-actin was performed for
the detection of TACE expression and activation. The TACE P-Thr735 was detected on 80 kDa band. Blots are representative of four experiments and normalized values with actin
band obtained by densitometric analysis of four experiments are reported in the bottom. The values are the mean percentage SEM relative to those obtained in the untreated
and unstimulated cells (control, 100%).
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inflammation. Then, we speculate that this could be in part
responsible of the excessive recruitment of leukocytes in CD patient
intestine. In fact, an oxidative state condition is present also in
ISEMFs [Iantomasi et al., 1994; Catarzi et al., 2011a] as well as an
increase of ICAM-1 and sICAM-1 in CD intestinal tissue [Ghosh and
Panaccione, 2010]. The increase of sICAM-1 levels in conditions of
oxidative stress and/or TNFa stimulation suggests also that ISEMFs
can contribute in the enhancement of sICAM-1 levels in serum of
IBD patients. In fact, it has been demonstrated that the increase of
sICAM-1 in the blood of these patients is related to the levels present
in intestinal mucosa and derives from activated cells within gut
mucosa and not from circulating leukocytes [Nielsen et al., 1994;
Song et al., 2009]. NAC, down-regulating ICAM-1 expression and
sICAM-1 release in ISEMFs, can reduce the excessive recruitment of
immune cells in intestinal mucosa, the activation of inflammatory
cascade and angiogenesis, preventing the onset and the progression
of chronic inflammatory diseases [Lawson and Wolf, 2009; Angel-
Morales et al., 2012]. Moreover, the reduction of ICAM-1expression
and of its soluble form by antioxidants treatment could interfere
with the tumor differentiation and the metastasis development. In
fact, intestinal myofibroblasts regulate themigration, differentiation
and growth of normal and carcinoma cells [Pinchuk et al., 2010], and
the chronic inflammation can favor the development of colon cancer
[Grivennikov, 2013]. Since our results show that in TNFa stimulated
18Co cells NAC treatment reduces in part ICAM-1 expression and
sICAM-1 release, we speculate that the synergistic effect between the
antioxidants and anti- TNFa drugs could be therapeutically useful.
CONCLUSIONS
All together, our data demonstrate, for the first time in 18Co cells, an
up-regulation of ICAM-1 expression and sICAM-1 release induced
by oxidative stress and TNFa stimulation, showing a redox
regulation of these events. However, also redox-independent
mechanisms in ICAM-1 expression and release are probable in
TNFa stimulated cells. It was shown that cleavage of ICAM-1 on cell
surface is mediated by redox regulated MMPs. Moreover, we suggest
the possible involvement of TACE, whose expression and activation
in 18Co cells have been related to ROS levels. An involvement of
NADPH oxidase in the redox regulation of ICAM-1 and TACE has
been demonstrated.
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